Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antimicrobial Treatment for Ventilator-associated Tracheobronchitis (TAVeM2)
NCT03012360Phase 4Terminated
- Sponsor
- CHU de Lille
- Start
- Feb 2018
- Primary completion
- Jul 2024
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 4 trial of ceftriaxone, ciprofloxacin, imipenem, linezolid in ventilator-associated tracheobronchitis (VAT), sponsored by CHU de Lille. Started Feb 2018; status: terminated.
02
Drugs
ceftriaxoneciprofloxacinimipenemlinezolid
03
Conditions
ventilator-associated tracheobronchitis (VAT)
Beyond the preview
Go deeper on NCT03012360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03012360.